
|Articles|February 14, 2019
TARGET PharmaSolutions Launches Real-World Observational Study
Advertisement
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, launched its latest large-scale observational study, TARGET-DERM. The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis (AD/eczema). and vitiligo (loss of skin pigment).
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026 Panel Discussion: Diversity in Clinical Trials—What’s Working, What’s Next
2
SCOPE Summit 2026 Keynote Panel: Is Radical Acceleration in Clinical Research Possible?
3
SCOPE Summit 2026: Elevating Patient Experience in Clinical Operations
4
SCOPE Summit 2026: Reducing Patient Burden Is the Foundation of Wearable Success in Oncology
5




